SAUNDERS BRENT L

SEC source: 0001818093-21-000010 · wf-form4_162138732027201.xml · derivative · entry 5

SAUNDERS BRENT L · CIK 0001268854 · Director · 10% owner · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By BLS

Disclosed balance after: 0

Underlying: Class A Common Stock · 9,333,333 shares

Expires not disclosed

F1 · kind: Represents a distribution for no consideration by BLS Investor Group LLC ("BLS") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein.

F4 · derivative.exercise_date: The warrants are exercisable by the holder into shares of Class A Common Stock on a one-for-one basis commencing on 10/2/2021, and expire on 5/4/26 or earlier redemption or liquidation.

F4 · derivative.expiration_date: The warrants are exercisable by the holder into shares of Class A Common Stock on a one-for-one basis commencing on 10/2/2021, and expire on 5/4/26 or earlier redemption or liquidation.

F1 · ownership.direct: Represents a distribution for no consideration by BLS Investor Group LLC ("BLS") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein.

SEC source: 0001818093-21-000010 · wf-form4_162138732027201.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · 10% owner · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · By BLS

Disclosed balance after: 0

F1 · kind: Represents a distribution for no consideration by BLS Investor Group LLC ("BLS") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein.

F1 · ownership.direct: Represents a distribution for no consideration by BLS Investor Group LLC ("BLS") to its members in accordance with their respective interests. The reporting person is the managing member of BLS and may be deemed to beneficially own the shares held by BLS, but disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein.

SEC source: 0000899243-21-018999 · doc4.xml · derivative · entry 3

SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,860,000

Underlying: Common Stock · 1,860,000 shares

Expires 2031-05-06

F2 · security: Represents a grant of stock options under The Beauty Health Company 2021 Incentive Award Plan. Subject to accelerated vesting in certain circumstances, twenty-five percent (25%) of the stock options are scheduled to vest on each of the first four anniversaries of May 6, 2021, as long as the reporting person remains in the service of The Beauty Health Company through the applicable vesting date.

F2 · derivative.exercise_date: Represents a grant of stock options under The Beauty Health Company 2021 Incentive Award Plan. Subject to accelerated vesting in certain circumstances, twenty-five percent (25%) of the stock options are scheduled to vest on each of the first four anniversaries of May 6, 2021, as long as the reporting person remains in the service of The Beauty Health Company through the applicable vesting date.

SEC source: 0000899243-21-018999 · doc4.xml · derivative · entry 2

SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 11,500,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination. The securities reported are held of record by BLS Investor Group, LLC. The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC. The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F1 · derivative.expiration_date: The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination. The securities reported are held of record by BLS Investor Group, LLC. The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC. The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

F1 · ownership.nature: The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination. The securities reported are held of record by BLS Investor Group, LLC. The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC. The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0000899243-21-018999 · doc4.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 11,500,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The shares of Class B Common Stock converted into shares of Class A Common Stock on a one-for one basis upon the issuer's consummation of its initial business combination. The securities reported are held of record by BLS Investor Group, LLC. The reporting person is the managing member of BLS Investor Group, LLC. As such, the reporting person may be deemed to have beneficial ownership of the securities beneficially owned by BLS Investor Group, LLC. The reporting person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

SEC source: 0001209191-20-063336 · doc4.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,543

F1 · shares: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code.

F2 · balance_after: Includes 1,564 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock.

SEC source: 0001818093-21-000009 · wf-form4_162138684705746.xml · derivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · 10% owner · Executive Chairman

BLS Investor Group LLC · CIK 0001818155 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By BLS

Disclosed balance after: 9,333,333

Underlying: Class A Common Stock · 9,333,333 shares

Expires not disclosed

F1 · derivative.exercise_date: Represents warrants to purchase Class A Common Stock issued to BLS Investor Group LLC ("BLS") in connection with the Issuer's initial public offering pursuant to the Registration Statement on Form S-1, as amended and filed with the SEC on September 21, 2020 (the "Registration Statement"). Brenton L. Saunders is the managing member of BLS and may be deemed to beneficially own the shares held by BLS. Mr. Saunders disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein.

F1 · derivative.expiration_date: Represents warrants to purchase Class A Common Stock issued to BLS Investor Group LLC ("BLS") in connection with the Issuer's initial public offering pursuant to the Registration Statement on Form S-1, as amended and filed with the SEC on September 21, 2020 (the "Registration Statement"). Brenton L. Saunders is the managing member of BLS and may be deemed to beneficially own the shares held by BLS. Mr. Saunders disclaims beneficial ownership of such securities except to any pecuniary interest he may have therein.

F2 · ownership.direct: The warrants are exercisable by the holder into shares of Class A Common Stock on a one-for-one basis commencing on the later of 12 months from the closing of the IPO or 30 days after the completion of our initial business combination, and expire five years after the completion of our initial business combination or earlier upon redemption or liquidation, each as described in the Registration Statement.

SEC source: 0000899243-20-017666 · doc4.xml · derivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,223

Underlying: Common Stock · 101,223 shares

Expires 2030-06-22

F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in three annual installments after June 23, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 12

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 83,936 shares

Expires not disclosed

F5 · derivative.exercise_price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

F5 · price: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

F5 · derivative.exercise_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

F5 · derivative.expiration_date: Reflects the disposition of performance stock units relating to Allergan Shares ("Allergan PSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target).

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 11

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1 shares

Expires 2024-05-12

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 10

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 62,547 shares

Expires 2024-05-12

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 9

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 219,667 shares

Expires 2023-09-30

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 8

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,790 shares

Expires 2023-08-14

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 7

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,691 shares

Expires 2022-08-22

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 6

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 9,446 shares

Expires 2021-08-22

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 5

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,018 shares

Expires 2024-05-12

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 4

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,291 shares

Expires 2023-09-30

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · derivative · entry 3

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 104,651 shares

Expires 2023-05-08

F4 · price: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

F3 · derivative.exercise_date: All of the stock options to purchase Allergan Shares ("Allergan Options") were vested as of May 8, 2020.

F4 · derivative.exercise_date: Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · nonDerivative · entry 2

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · balance_after: Reflects the disposition of restricted stock units relating to Allergan Shares ("Allergan RSUs") as contemplated by the Transaction Agreement. In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement.

SEC source: 0000899243-20-012730 · doc4.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · balance_after: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.

SEC source: 0001179110-20-003037 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,189.29

F1 · balance_after: Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-20-000039 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,576.29

F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001567619-19-023022 · doc1.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,653

F1 · shares: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code.

F2 · balance_after: Includes 863 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock.

SEC source: 0001179110-19-004798 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,909.29

F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-19-003505 · edgar.xml · nonDerivative · entry 3

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,666.29

F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $144.15 to $144.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-19-003505 · edgar.xml · nonDerivative · entry 2

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,066.29

F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $143.13 to $143.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-19-003505 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,206.29

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $142.09 to $142.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote

F4 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-19-000199 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,906.29

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001567619-18-008032 · doc1.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,014

F1 · shares: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code.

F2 · balance_after: Includes 439 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock.

SEC source: 0000903423-18-000201 · saundersf4.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 178,175.29

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-18-003827 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,931.29

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-18-000111 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,631.29

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001140361-17-046098 · doc1.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,956

F1 · shares: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code.

F2 · balance_after: Includes 125 dividend equivalents accrued on vested deferred restricted stock units. Each dividend equivalent is the economic equivalent of one share of Cisco common stock.

SEC source: 0001179110-17-014997 · edgar.xml · nonDerivative · entry 2

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,377.29

F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-014997 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,177.29

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.34 to $165.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-013555 · edgar.xml · derivative · entry 2

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 50,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F2 · derivative.exercise_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F2 · derivative.expiration_date: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

SEC source: 0001179110-17-013555 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,777.29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019.

F2 · price: Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person.

F3 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-012396 · edgar.xml · nonDerivative · entry 2

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,178.29

F2 · balance_after: Includes 43.7680 shares acquired on June 16, 2017 pursuant to a broker-assisted dividend reinvestment plan.

F3 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-007337 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,092

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-005550 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,542

F1 · shares: The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty percent (20%) on April 3, 2018, twenty percent (20%) on April 3, 2019, twenty percent (20%) on April 3, 2020, twenty percent (20%) on April 3, 2021 and twenty percent (20%) on April 3, 2022.

F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-17-012396 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · Chairman, President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,134.52

F1 · balance_after: Includes 42.52 shares acquired on March 29, 2017 pursuant to a broker-assisted dividend reinvestment plan.

F3 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001140361-17-011969 · doc1.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,168

F1 · shares: Represents a fully vested deferred restricted stock unit award covering shares which will settle in shares on, or as soon as practicable after, the reporting person's "separation from service" to Cisco within the meaning of Section 409A of the Internal Revenue Code.

SEC source: 0001179110-16-031890 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,564

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $188.43 to $189.81, inclusive. The reporting person undertakes to provide Allergan plc, any security holder of Allergan plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price range set forth in footnote (1) of this Form 4.

F2 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001179110-16-030198 · edgar.xml · nonDerivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,314

F1 · balance_after: Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.

SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 9

SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 65,587.15 shares

Expires not disclosed

F4 · derivative.exercise_price: Each unit of phantom stock is the economic equivalent of one share of common stock.

F5 · price: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

F5 · derivative.exercise_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

F5 · derivative.expiration_date: In connection with the Merger, each unit of phantom stock was converted into 0.5767 phantom shares of Merck & Co., Inc. common stock and $10.50 in cash. The cash value of the phantom stock units will be paid to the reporting person in accordance with the reporting person's distribution election under the Issuer's nonqualified deferred compensation plan.

SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 8

SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 130,100 shares

Expires 2016-04-30

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.

SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 7

SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 130,000 shares

Expires 2015-04-30

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.

SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 6

SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 130,000 shares

Expires 2015-04-24

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.

SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 5

SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 140,000 shares

Expires 2014-04-30

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.

SEC source: 0001209191-09-051079 · c91857_4x1.xml · derivative · entry 4

SAUNDERS BRENT L · CIK 0001268854 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 100,000 shares

Expires 2014-02-22

F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Merck & Co., Inc. in accordance with the exchange ratio set forth in the Merger Agreement.

F2 · derivative.exercise_date: The options vested and became exercisable (or will vest and become exercisable) on varying dates pursuant to the terms of the plans under which they were granted. Options that had not vested prior to the Merger, vested upon the closing of the Merger or will vest upon the reporting person's termination of employment thereafter.